Community Oncologist Perspective: Clinical Recommendations for Neurological Toxicities

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management, also addressing other important toxicities.

EP: 1.Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

EP: 2.CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing

EP: 3.Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

EP: 4.Protocol Development for Administration and AE Management of Bispecifics

EP: 5.Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management

EP: 6.Exploring the Management of Cytokine Release Syndrome (CRS)

EP: 7.Academic Perspectives for Evaluating, Identifying, and Managing CRS

EP: 8.Community Oncologist Perspective: Evaluating, Identifying, and Managing CRS

EP: 9.Clinical Recommendations for Neurological Toxicities

Now Viewing

EP: 10.Community Oncologist Perspective: Clinical Recommendations for Neurological Toxicities

EP: 11.Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications

EP: 12.Community Oncologist Perspective: Initiation, Hospitalization, and Monitoring of Bispecifics

EP: 13.Patient Referrals of Bispecifics and Collaborative Efforts with Community Centers

EP: 14.Perceptions on the Future of Bispecific Therapies for NHL

EP: 15.Community Oncologist Perspective: Future of Bispecific Therapies for NHL

Video content above is prompted by the following:

1. Review the recommendations on identifying, evaluating, and managing neurological toxicities.

• Workup and evaluation
• Grading of neurological toxicity
• Management of neurological toxicities
• Are there any other toxicities that are important to mention?

Recent Videos